Synaptic phospholipids as a new target for cortical hyperexcitability and E/I balance in psychiatric disorders

Carine Thalman, Guilherme Horta, Lianyong Qiao, Heiko Endle, Irmgard Tegeder, Hong Cheng, Gregor Laube, Torfi Sigrudsson, Maria Jelena Hauser, Stefan Tenzer, Ute Distler, Junken Aoki, Andrew J. Morris, Gerd Geisslinger, Jochen Röper, Sergei Kirischuk, Heiko J. Luhmann, Konstantin Radyushkin, Robert Nitsch, Johannes Vogt

Producción científica: Articlerevisión exhaustiva

46 Citas (Scopus)

Resumen

Lysophosphatidic acid (LPA) is a synaptic phospholipid, which regulates cortical excitation/inhibition (E/I) balance and controls sensory information processing in mice and man. Altered synaptic LPA signaling was shown to be associated with psychiatric disorders. Here, we show that the LPA-synthesizing enzyme autotaxin (ATX) is expressed in the astrocytic compartment of excitatory synapses and modulates glutamatergic transmission. In astrocytes, ATX is sorted toward fine astrocytic processes and transported to excitatory but not inhibitory synapses. This ATX sorting, as well as the enzymatic activity of astrocyte-derived ATX are dynamically regulated by neuronal activity via astrocytic glutamate receptors. Pharmacological and genetic ATX inhibition both rescued schizophrenia-related hyperexcitability syndromes caused by altered bioactive lipid signaling in two genetic mouse models for psychiatric disorders. Interestingly, ATX inhibition did not affect naive animals. However, as our data suggested that pharmacological ATX inhibition is a general method to reverse cortical excitability, we applied ATX inhibition in a ketamine model of schizophrenia and rescued thereby the electrophysiological and behavioral schizophrenia-like phenotype. Our data show that astrocytic ATX is a novel modulator of glutamatergic transmission and that targeting ATX might be a versatile strategy for a novel drug therapy to treat cortical hyperexcitability in psychiatric disorders.

Idioma originalEnglish
Páginas (desde-hasta)1699-1710
Número de páginas12
PublicaciónMolecular Psychiatry
Volumen23
N.º8
DOI
EstadoPublished - ago 1 2018

Nota bibliográfica

Publisher Copyright:
© 2018, Macmillan Publishers Limited, part of Springer Nature.

Financiación

Acknowledgements We thank Cheryl Ernest for proofreading the manuscript, Silke Fregin for technical assistance and Nicolai Savaskan for providing the ATX-GFP construct. This work was supported by the Deutsche Forschungsgemeinschaft (SFB 1080 and 1193) to JV, RN, IT, JR, TS, KR and HJL, by the European Research Council (ERC-AG \u201CLiPsyD\u201D to RN) and by the Boehringer-Ingelheim Foundation to JV.

FinanciadoresNúmero del financiador
Boehringer-Ingelheim Foundation
H2020 European Research Council
U.S. Department of Veterans AffairsI01CX001550
U.S. Department of Veterans Affairs
National Institute of General Medical Sciences DP2GM119177 Sophie Dumont National Institute of General Medical SciencesP30GM127211, P20GM103527
National Institute of General Medical Sciences DP2GM119177 Sophie Dumont National Institute of General Medical Sciences
European Commission322907
European Commission
Deutsche ForschungsgemeinschaftSFB 1080, 1193
Deutsche Forschungsgemeinschaft

    ASJC Scopus subject areas

    • Molecular Biology
    • Cellular and Molecular Neuroscience
    • Psychiatry and Mental health

    Huella

    Profundice en los temas de investigación de 'Synaptic phospholipids as a new target for cortical hyperexcitability and E/I balance in psychiatric disorders'. En conjunto forman una huella única.

    Citar esto